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MANAGING END-OF-LIFE PAIN USING A RECTAL
MEDICATION ADMINISTRATION DEVICE

Abstract
Approximately 75% of the terminally ill will experience pain during the
dying process. Oral opioids are the mainstay of pain management; however,
patients are often unable to tolerate oral medications at the end of life and
will need an alternate route of medication administration. Rectal
administration is an appropriate alternative. End-of-life patients unable to
tolerate oral pain medications were switched to the rectal route using a rectal
medication administration device for pain management. Although only four
patients participated in the pilot project, all patients experienced a decrease
in pain level. Pain medication administration using a rectal medication
administration device is a viable alternate route and is low cost, easy to use,
and effective for dying patients for whom oral medication administration is
not appropriate.
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End-of-life issues, pain management, rectal tube, rectal medication
administration device, end-of-life symptom management, hospice
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Managing end-of-life pain using a rectal medication administration
device

In 2013, the National Hospice and Palliative Care Organization
estimated 1.5 to 1.6 million patients had received hospice care1. Ensuring a
good death is a major challenge for healthcare providers2. Six major
components of a good death include pain symptom management, clear
decision making, preparation for death, completion, contributing to others,
and affirmation of the whole person3. Approximately 75% of terminally ill
patients will experience pain at the end of life4. Pain is a common symptom
during the end of life; therefore, pain management is a key element in endof-life care. “Good management of physical symptoms allows patients and
loved ones the space to work out unfinished emotional, psychological, and
spiritual issues, and thereby, the opportunity to find affirmation at life’s
end”5(p.1059).

Pain control is a challenging task for end-of-life care, and,
unfortunately, pain is often untreated or undertreated6. Effective pain
management may necessitate a variety of control strategies6. Groninger and
Vijayan emphasized the necessity for strong opioids for effective analgesia
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in dying patients7. Oral opioids are the preferred method of pain
management in hospice care8; however, end-of-life patients are often unable
to tolerate oral routes due to loss of consciousness, inability to swallow, fear
of aspiration, or too many medications. Warren noted that “persistent
inability to utilize the oral route is most common when death is imminent”9(p.
378)

.

These patients will need an alternate route of medication
administration, and the rectum provides a viable alternative. The rectal route
has several benefits including low cost, consistent and predictable absorption
of medications, ease of use, and good symptom management10. Rectally
administered medications are as effective or, in some cases, more effective
than oral medications11. The rectal route has a rapid onset of action, is safe,
easy, and generally painless, and there is no risk of aspiration. Rectal
administration also bypasses first pass metabolism and the protein peptide
drug delivery system12. Almost all oral medications can be given rectally13,
and oral medications are significantly cheaper than other forms, such as
sublingual, transdermal, or intravenous.
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The Local Problem
Currently, patients unable to tolerate oral medications are switched to
sublingual or subcutaneous routes (SQ). The transdermal route is not
considered for pain management in end-of-life patients, due to the long
period required for sufficient absorption to achieve pain relief. For example,
Fentanyl patches can provide adequate pain control but take approximately
12 hours to become effective. Such delays are not acceptable for patients in
the last hours to days of life6. Similarly, sublingual (SL) medications are not
always effective in end-of-life patients for a variety of reasons. Some of
these reasons include inadequate absorption of SL medications in patients
with extremely dry mucus membranes, inappropriate use of SL medications
by caregivers, or pocketing of medications in patient’s cheeks, which poses a
risk for aspiration. Subcutaneous (SQ) medications are effective for end-oflife pain management; however, supplies and medications for the SQ route
are expensive. Due to these many factors, a need for an alternative route for
pain medication management between the oral and SQ routes was identified
in the hospice setting.

Each patient that is placed on a subcutaneous button is a patient that
would be eligible for a rectal medication administration device (RMAD).
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Patients using a subcutaneous button are placed in crisis care, meaning that
they need daily follow up by a provider and sometimes a bedside nurse for
symptom management. The number of crisis care patients and the number of
patients using a subcutaneous button each month was tallied. Over a 3month period, the number of patients on crisis care ranged from 42 to 45,
and the number with a subcutaneous button ranged from 13 to 19. During
the time period, at least a third of the patients on crisis care were using
subcutaneous buttons.

Patients unable to tolerate oral medication administration were being
changed from oral directly to subcutaneous pain medications, the only other
routes available were sublingual or transdermal routes, and not all
medications are effective via those routes. Patients often waited a long time
before subcutaneous medications could be started. Subcutaneous button
supplies need to be ordered and were often not stocked in case managers’
supplies. Subcutaneous medications need to be ordered and picked up or
delivered from the pharmacy, which could take six hours or longer. These
patients needed a faster alternative as a possible step between the oral and
subcutaneous routes.
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Purpose
The purpose of this evidence-based project was to improve end-of-life
pain management in hospice patients experiencing uncontrolled pain using a
rectal medication administration device.

Ethical Issues
Approval to implement the project was obtained from the
administration of a large southern California hospice organization. In
addition, approval to disseminate de-identified data was obtained from the
University of San Diego Institutional Review Board.

Setting
This project was conducted at one of the oldest and largest nonprofit
hospices in southern California. The organization provides hospice and
palliative care services to San Diego and south Riverside counties. Each
patient has a support team that includes hospice-trained physicians and nurse
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practitioners, nurses trained in pain control and symptom management,
hospice aides, social workers, spiritual counselors, and volunteers.

Practice Change
Several activities were involved in implementing the practice change.
These included formation of a RMAD task force, creation of the RMAD
device, identifying appropriate medications, developing a standard of
practice, developing documentation forms, creating training materials,
training staff, and implementing use of the device. Each of these activities is
discussed below.

Task Force Formation
An interdisciplinary task force representing all stakeholders was
appointed to coordinate the RMAD project. The project was chaired by a
doctorally prepared nurse practitioner that acted as the project coordinator,
clinical mentor, and guide. Other members of the task force included
registered nurses, licensed vocational nurses, social workers, and chaplains.
Task force members met monthly to keep up to date with the progress of the
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project and provided feedback for project development. Each task force
member was given a task to help expedite the project. Examples of tasks
included creating a RMAD, identifying possible pain medications to be used
with the device, narrowing participant criteria, and determining possible
barriers to use of a rectal device.

Creating the Device
The rectal route was determined to be a suitable alternate route and a
device was put together to help deliver the pain medication. Using the
company-approved supply vendor, several possible devices were tested and
a final device approved by the task force. Cost, ease of use, accessibility, and
reproducibility were all factors in the selection of the final RMAD. The
RMAD was created with a 16 French Foley catheter, a Luer tip catheter
adapter, and a 3-way stopcock. The port for the urine collection device was
removed from the Foley catheter and a Luer tip catheter adapter inserted.
The 3-way stopcock was then attached to the Luer tip end of the adapter.
Instructions for creating the device are shown in Figure 1, and the final
RMAD is depicted in Figure 2.
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Identifying RMAD medications
The RMAD pain medication formulary is based on the current
emergency kit at the setting. The goal was to be able to use medications that
were already available in a patient’s home. Each of the medications
available in the emergency kit, as well as commonly used opioids and other
pain medications, were thoroughly researched for efficacy and safety of use
for the rectal route. The head pharmacist at the company-approved pharmacy
was consulted throughout this process about rectal use and efficacy of each
medication.

Developing an RMAD standard of practice
The existing protocol for medication administration via subcutaneous
button was used as a guideline for developing a standard of practice for the
RMAD. The standard of practice was reviewed during task force meetings
and corrections were made and finalized. The RMAD standard of practice is
the guide for all staff and family members for use of a RMAD. The standard
of practice describes the purpose of the device and how to contact the
appropriate staff member for the provider’s order to change the medication
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route. It also lists what is included in each RMAD kit and provides step-bystep instructions on how to create the final device from the contents of the
kit. Detailed instructions for RMAD insertion and removal, medication
preparation, and medication administration are also included in the standard
of practice. A list of RMAD medications is also included.

Creating Documentation Forms
A variety of documentation forms and teaching materials were needed
to implement the project. RMAD forms were created based on the need to
monitor pain levels. Forms created included a caregiver profile, medication
form, and the RMAD evaluation form. The caregiver profile elicits
background information about caregivers that is useful in determining the
appropriateness of RMAD, such as education level, familiarity with route of
medication administration, physical limitations and ability to use the
RMAD, comfort with medication administration, and so on. The medication
form was developed to monitor types of medication used, amount of water
used for each administration, and FLACC pain scale before and after
medication administration using the RMAD. The RMAD evaluation form
provides feedback on how well managed the patient’s pain is using the
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RMAD and any questions, concerns, or complications that may arise during
therapy. All RMAD forms were presented to the site’s clinical operations
quality team for approval and adoption. Copies of the final version of all
RMAD forms were branded for site use.

Developing Training Materials
The RMAD training handbook is a one page, front and back, guide
that provides easy step-by-step instructions at a third grade level for RMAD
insertion, medication preparation, and medication administration. The
training handbook was intended to be a quick reference for patients’
caregivers and for staff with pertinent RMAD information, such as what a
RMAD is, RMAD insertion, medication preparation, and medication
administration via RMAD. The front section provided information about the
device and what is in each RMAD kit. The second section included how to
insert the device, how to prepare medications to be used, and how to give the
prepared medications using the RMAD. Each caregiver was trained using
this handbook and demonstrated verbal and written understanding of how to
prepare and give medications using the RMAD.
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Training RMAD Champions and Triage Staff
Registered nurse case managers (RNCMs) volunteered to participate
in the RMAD pilot project. Two nurses from each geographic area served by
the agency were chosen to be project champions and were trained on the
RMAD and all forms. Triage staff members, including overnight triage staff,
were also trained on the RMAD in case they needed to replace the device
after hours or a patient was admitted that was eligible for RMAD use.

Implementing Use of the RMAD
Eligibility criteria for patients’ use of an RMAD included admission
to the hospice’s care, being actively engaged in the dying process (in the last
hours to days of life), and with an inability to swallow, uncontrolled nausea
or vomiting, or pain uncontrolled by other routes except the subcutaneous
route. These patients and their family members were educated about the
RMAD by a RMAD champion, and, if they agreed to participate, a RMAD
was inserted. The patient was changed to crisis care status for the first 24
hours after RMAD placement to monitor pain levels and assure that patients
and caregivers had adequate support, if needed. Caregivers who were
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comfortable with management of medications through the RMAD were
trained to prepare and administer medications and did not need a bedside
nurse. Caregivers were not trained to insert the device; only the hospice staff
was allowed to insert the RMAD. Patients were monitored on the RMAD on
days 1, 2, 3, and 6 after insertion or earlier if complications occurred.

Evaluating Project Results
The main purpose of this project was to improve pain management
using a RMAD. The overall goal was a decrease in pain levels for patients
using RMAD. Specific objectives for this project included: (a) a decrease in
pain level in 80% of patients, (b) participation of 60% of RMAD eligible
patients in the program, and (c) participation of 50% of providers in the
program.

Evaluation of the effectiveness of this program included whether the
RMAD was a device that would be accepted by patients, caregivers, and
staff and the cost-benefit of using a RMAD versus a subcutaneous button.
Evaluation of the RMAD included review of RMAD packets to evaluate
pain levels and speaking with caregivers and staff about their opinions of the
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device and rectal route. The RMAD packets were a folder that included all
the RMAD forms – caregiver profile, RMAD standard of practice, RMAD
training handbook, RMAD medication sheet, and RMAD evaluation form.
Cost analysis for the RMAD compared to the subcutaneous button was
based on the cost of the kits and the medications involved.

Evaluation Findings
Objectives a and c were both met. All participating patients
experienced a decrease in pain levels using a RMAD (see Figure 3) and
100% of the providers participated in the program. Unfortunately, only 11%
of RMAD-eligible patients participated in the project (see Figure 4). Some
reasons for not participating in the program included staff members that
were not familiar with the device and did not want to use it. Staff members
unfamiliar with the rectal route also raised doubts in caregivers and often
talked them out of using the rectal route once they had agreed. Some
caregivers were adamantly against the rectal route for their loved one, and
some patients passed before a RMAD champion could get them enrolled in
the program.
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A cost comparison for the RMAD versus the subcutaneous button
showed a savings of $14.34 for the kit and $149.09 for medications. Further
savings derive from the fact that the subcutaneous button needs to be
changed every three days and usually there are two buttons placed because
some medications are caustic and cannot be run through the same device.
The RMAD does not need to be replaced unless it becomes clogged or is
removed and even then, the only part that needs to be replaced is the catheter
itself, at a cost of $0.86. The bulk price for the subcutaneous button kit was
$17 and the individual pricing for all the components of a RMAD kit totaled
$2.66. If the RMAD were to be packaged as a self-contained kit, as are the
subcutaneous button kits, instead of piece-meal ordering, the estimated cost
per kit at bulk prices would be less than $1. The average cost of medications
for the subcutaneous button is $180 for methadone, morphine, Ativan, and
haloperidol. The RMAD only uses medications from the emergency kit at a
cost of $30.

Discussion
Continuation of RMAD use would provide an alternate route of
medication administration that is easy to use, efficient, and cost effective.
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Every patient experienced a decrease in pain levels, which means that pain
management was successful using a RMAD. The device is simple to put
together and also much more portable for RN case managers (RNCMs).
Using the available emergency medication kit that patients already have in
their house eliminates the need to wait for medications.

Some limitations of the project included time constraints, patient
participation, and general attitude towards the rectal route on the part of both
staff and caregivers. The project was started during first week of December
2014 and ended in Feb 2015. Patient participation could have been affected
by RMAD eligibility criteria. In general, staff did not feel that eligibility
criteria for patient participation in the program were too strict. However,
there were some concerns about whether the patient needed to meet all
criteria or a few of the criteria. For this program the main criteria were that
the patient was actively dying and had pain that could not be managed
through other methods.

The biggest obstacle to program implementation was overcoming
negative caregiver and staff attitudes toward using the rectal route. Staff
attitude was an unexpected barrier. LVNs who were uncomfortable with the
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device essentially talked the caregivers out of using the rectal device because
the LVNs would be the ones maintaining the RMAD if the caregivers were
not comfortable with medication administration via RMAD. Other staff
simply refused to use a RMAD and were not even open to education about
the device. Additional champions were needed and trained about halfway
through the project. A few patients were eligible but because their RNCM
was not RMAD trained, they needed to contact a RMAD champion, and the
patients expired by the time a champion could get to the site.

Several lessons were learned as a result of this project, the biggest
lesson being the need to be adaptable. Many factors came up during the time
from project initiation to the end. A good environment and site support was
crucial to implementation of this project. Initiating this project as a pilot
program was both good and bad. Starting as a pilot meant that the
availability of the device to the entire site was limited, this was a problem
because not enough staff was exposed to the device; greater exposure might
have eliminated the uncertainties some staff had about the device. On the
other hand, keeping the project small meant that not everyone was trying to
use the device on every patient, which helped to keep variables low. The
most useful comment from a RMAD champion was to start talking about the
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device earlier in the patient’s care so this new and often stigmatized route is
not introduced to the caregiver when they are overwhelmed with their loved
one dying.

CONCLUSIONS/IMPLICATIONS
Having an additional route for medication administration is vital.
Although many people are averse to using the rectal route, more education
needs to be done for medical professionals and caregivers about the ease and
effectiveness of rectal administration using a RMAD. Using a RMAD
eliminates the need for caregivers to keep turning their loved ones and to
constantly be giving rectal suppositories. This creates an increase in patient
and caregiver satisfaction. Future research can be done using different types
of medications and/or different populations of patients. More effective
modes of educating caregivers and staff regarding RMAD use can also be
studied.

More education of the general population is also needed. The rectal
route is important not only in end-of-life care, but has the potential to be
used in other situations, such as a patient with uncontrolled nausea and
vomiting. This route has the potential to serve many patients.
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6.

Figure 1. How to Create the RMAD. 1. Unwrap foley catheter. 2. Remove
plug from urine collection port of the catheter. 3. Insert Luer tip adapter in
urine collection port of catheter. 4. Make sure Luer tip adapter fits snugly
into catheter. 5. Attach stopcock to Luer tip adapter. 6. Screw stopcock
tightly to adapter.
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Figure 2. Final RMAD.
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Figure 3. Pain levels during RMAD intervention.
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Figure 4. Number of patients using specific administration routes before and
during intervention.
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Purpose: The purpose of this project was to improve end-of-life pain
management among hospice patients using a rectal medication
administration device (RMAD).

Background: Approximately 1.5 to 1.6 million patients received hospice
services in 2013 (National Hospice and Palliative Care Organization, 2013),
and almost 75% of terminally ill patients experience pain during the dying
process (Fink & Gates, 2010). Patients are often unable to tolerate oral pain
medications at the end of life. Rectal administration of medication is an
appropriate alternative for these patients. The rectal route has several
benefits including low cost, consistent and predictable absorption of
medications, ease of use, and good symptom management (Davis, Walsh,
LeGrand, & Naughton, 2002).

Approach: End-of-life patients unable to tolerate oral pain medications are
currently switched to a subcutaneous button route. These patients will be
offered the RMAD as an alternative before the subcutaneous button is used.
After consent is obtained for use, patients will have a trained licensed nurse
place the device and sit bedside to administer the medications until the
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patient’s status changes. Pain levels will be monitored before and after
medication administration using the FLACC scale.

Outcomes: A total of four patients over 3 months, 100% of the patients
experienced a decrease in pain scores.

Conclusion: This program showed that a RMAD device is useful for pain
medication administration and resulted in a decrease in pain levels in all four
participants. Continuation of RMAD use would provide an alternate route of
medication administration that is easy to use, efficient, and cost effective
when oral medication administration is not appropriate.

References:
Davis, M. P., Walsh, D., Legrand, S. B., & Naughton, M. (2002). Symptom
control in cancer patients: The clinical pharmacology and therapeutic role
of suppositories and rectal suspensions. Support Cancer Care, 10, 117138. doi: 10.1007/s00520-001-0311-6
Fink, M.J., & Gates, R. A. (2010). Pain Assessment. In B. R. Ferrell & N.
Coyle (Eds.), Oxford textbook of palliative nursing (pp. 137-160). New
York, NY: Oxford University Press.
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National Hospice and Palliative Care Organization. (2013). NHPCO’s facts
and figures: Hospice care in America. Retrieved from
http://www.nhpco.org/sites/default/files/public/Statistics_Research/2013_
Facts_Figures.pdf
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BACKGROUND

Compared pain levels before, during, and after therapy using
FLACC scores.
Pain levels measured 30 minutes after pain medications
administered via RMAD.

EVALUATION METHOD

Rectal administration of medications is an appropriate alternative
for patients that are unable to tolerate oral medications at the end
of life.
The efficacy and safety of the rectal route is comparable to the
oral route (Radbruch et al, 2010).
Pain relief can be up to six times faster for rectal versus oral routes
(DeConno et al, 1995).
Benefits of the rectal route include low cost, consistent and
predictable absorption of medications, ease of use, and good
symptom management (Davis, Walsh, LeGrand, & Naughton,
2002).
Complications of the rectal route are usually localized and are
uncommon (Davis, Walsh, LeGrand, & Naughton, 2002).
The rectal route of administration is applicable to almost the
entire population of patients and almost any pill can be given
rectally (Samala & Davis, 2012).
The only absolute contraindications for rectal administration are
diarrhea, anorectal disease, previous abdominoperineal resection,
neutropenia, and thrombocytopenia (Davis, Walsh, LeGrand, &
Naughton, 2002).

EVIDENCE

To improve end-of-life pain management using a rectal
medication administration device (RMAD) in hospice patients.

AIM/PURPOSE

In 2013, approximately 1.5-1.6 million patients received hospice
services (NHPCHO, 2013).
Almost 75% of terminally ill patients experienced pain during the
dying process (Fink & Gates, 2010).
Pain is a common symptom during the end of life and
management of pain is a key element in end-of-life care.
Untreated pain can be a source of distress for the patient, the
patient’s family, and other caregivers.
End-of-life patients are often unable to tolerate oral medications
due to a change in mental status, a nonresponsive or comatose
state, difficulty or inability swallowing, the risk of aspiration, and
so on.

•

•

•

•
•
•
•
•

•
•

•

•
•

•
•
•

•
•
•

Rectal medication administration
device (RMAD)

Small number of participants
Limited amount of time for pilot program
Limited number of RMAD champions for a large patient
population – needed to train more champions halfway into
the program
Difficulty explaining device
Rectal route stigma
Staff not on RMAD pilot team not educated well enough to
provide information to caregivers
Some staff uncomfortable with device and rectal route
Introduce RMAD earlier in care instead of at the end when
family/caregivers might be overwhelmed

LIMITATIONS and LESSONS
LEARNED

Identified the need for an alternative route of pain medication
administration before the subcutaneous route.
Identified the most common types of pain medication used.
Identified the number of patients placed on crisis care (CC) for
pain management.
Identified an alternative route that is currently not being used.
Created a rectal medication administration device (RMAD) kit.
Wrote a standard of practice for RMAD.
Educated pilot team of providers and nurses – RMAD champions.
With the help of the pilot team, identified patients with
uncontrolled pain eligible for RMAD.
Changed route of administration for pain medication according to
standard of practice.
Licensed registered nurses from project site placed RMAD and
monitored pain levels during therapy.
Caregivers were taught to administer medication if they felt
comfortable with the process and received training from a RMAD
champion.
•
•

•
•
•

Pain levels during RMAD intervention

TABLES and GRAPHS

Total of 4 patients participated in RMAD pilot
100% of patients with decreased pain scores (see graph below)
Pain medication used: Morphine 15mg, although all emergency
kit medications and any previous pain medications were
available for use
No side effects noted
Patient/provider/caretaker comments
• Device easy to use and convenient
• Loose cap on stopcock
• Rectal route preferred over sublingual by 2/3 caregivers
• Patient dignity intact – patient could be covered with diaper
• “It worked wonderfully” – caregiver
• RN’s preferred rectal route to sublingual route
• Family immediately accepted rectal route and very please with
ease of administration

RESULTS

Jacqueline Copeland, DNP, MSN, APRN, FNP

PRACTICE INNOVATION

Mary Jo Clark, PhD, RN

Yen Tse, BSN, RN, DNP Student
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Continuation of RMAD use would provide an alternative route
of medication administration that is easy to use, efficient, and
cost effective.
Increase in patient satisfaction due to decreased cost of system
and medications, appropriate pain management, rapid
symptom control, and decreased care giver burden.
Ability to use RMAD for other types of medications, patients,
and settings.
Apply for patent for device.
Alternate route of medication administration before more
invasive routes such as subcutaneous or intravenous.
Small sample size could be a result of lack of education of staff,
this provides a teaching and learning opportunity for staff as
well as caregivers.
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CONCLUSIONS/IMPLICATIONS FOR
CLINICAL PRACTICE

Managing End-of-Life Pain using a Rectal Medication Administration Device
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BACKGROUND+
• Almost'75%'of'terminally'ill'pa3ents'experience'pain'during'the'dying'
process'
• End;of;life'pa3ents'are'o<en'unable'to'tolerate'oral'medica3ons'due'
to'a'change'in'mental'status,'a'nonresponsive'or'comatose'state,'
diﬃculty'swallowing'or'inability'to'swallow,'increased'risk'for'
aspira3on,'etc'
• Rectal'administra3on'of'medica3ons'is'an'appropriate'alterna3ve'for'
pa3ents'that'are'unable'to'tolerate'oral'medica3ons'at'the'end'of'life'
• Eﬃcacy'&'safety'of'the'rectal'route'is'comparable'to'the'oral'route'
• Complica3ons'of'the'rectal'route'are'usually'localized'&'are'
uncommon'
• Rectal'route'is'applicable'to'almost'the'en3re'popula3on'of'pa3ents'&'
almost'any'pill'can'be'given'rectally'
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AIM/PURPOSE+

To#improve#end,of,life#pain#management#using#a#
rectal#medica5on#administra5on#device#(RMAD)#in#
hospice#pa5ents.#

PRACTICE(INNOVATION(
• Establish)need)for)alternate)route)
• Create)task)force)for)RMAD)
• RMAD)
• Iden9fy)medica9ons)to)be)used)
• Forms)
• Target)pa9ent)popula9on)
• Standard)of)prac9ce)
• Train)RMAD)Champions)
• Ini9ate)pilot)program)
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RMAD%

RESULTS'
•
•
•
•
•

	
  

Total&of&4&pa*ents&par*cipated&
100%&of&pa*ents&had&decreased&pain&scores&
Medica*ons&used:&emergency&kit&
No&side&eﬀects&noted&
Caregiver/provider/staﬀ&comments&
• Device&easy&to&use&&&convenient&
• Loose&cap&on&stopcock&
• Rectal&route&preferred&over&sublingual&
by&2/3&caregivers&
• Pa*ent&dignity&intact&–&pa*ent&could&be&
covered&with&diaper&
• “it&worked&wonderfully”&–&caregiver&
• RN’s&preferred&rectal&route&to&sublingual&
• Family&immediately&accepted&rectal&
route&&&very&pleased&with&ease&of&
administra*on&
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COST%COMPARISON:%RMAD%VS%SQB%

RMAD%

SQB%

KIT$

$2.66$

$17$

MEDICATIONS$

$30$

$149.09$

LIMITATIONS)&)LESSONS)LEARNED)

• Small%number%of%par.cipants%
• Limited%amount%of%.me%for%pilot%program%
• Limited%number%of%RMAD%champions%for%a%large%pa.ent%
popula.on%–%needed%to%train%more%champions%halfway%into%
the%program%
• Diﬃculty%explaining%device%
• Rectal%route%s.gma%
• Staﬀ%uncomfortable%with%device%&%rectal%route%
• Introduce%RMAD%earlier%in%care%instead%of%at%the%end%when%
family/caregivers%might%be%overwhelmed%
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CONCLUSIONS/IMPLICATIONS-FORCLINICAL-PRACTICE• RMAD%would%provide%an%alternate%route%of%medica6on%
administra6on%that%is%easy%to%use,%eﬃcient,%&%cost%eﬀec6ve%
• Increase%in%pa6ent%sa6sfac6on%
• Ability%to%use%RMAD%for%other%types%of%medica6ons,%
pa6ents,%&%se@ngs%
• Patent%for%RMAD%

QUESTIONS?*
COMMENTS?*
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